<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: In <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri</z:e> (PTC), <z:e sem="disease" ids="C0151740" disease_type="Disease or Syndrome" abbrv="">elevated intracranial pressure</z:e> (ICP) results in <z:hpo ids='HP_0001085'>papilledema</z:hpo> and, rarely, <z:mp ids='MP_0005546'>choroidal neovascularization</z:mp> (CNV) </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">Pseudotumor cerebri</z:e>-induced CNV often regresses following medical or surgical ICP reduction, but additional treatments, such as photocoagulation, photodynamic therapy, peri-ocular steroid injections and/or subretinal surgery, may be necessary </plain></SENT>
<SENT sid="2" pm="."><plain>Anti-angiogenic intravitreal injections have been shown to cause regression of both CNV and optic nerve <z:hpo ids='HP_0000969'>edema</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>CASE REPORT: We describe a patient with PTC and CNV whose CNV regressed and vision normalized after a single intravitreal injection of bevacizumab (Avastin; Genentech, San Francisco, CA) </plain></SENT>
</text></document>